0001562180-21-004395.txt : 20210621
0001562180-21-004395.hdr.sgml : 20210621
20210621160607
ACCESSION NUMBER: 0001562180-21-004395
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20210617
FILED AS OF DATE: 20210621
DATE AS OF CHANGE: 20210621
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: RUDNICK SETH
CENTRAL INDEX KEY: 0001184420
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38096
FILM NUMBER: 211030523
MAIL ADDRESS:
STREET 1: 7100 WEST CREDIT AVENUE, SUITE 101
STREET 2: C/O ARALEZ PHARMACEUTICALS
CITY: MISSISSAUGA
STATE: A6
ZIP: L5N 0E4
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: G1 Therapeutics, Inc.
CENTRAL INDEX KEY: 0001560241
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 263648180
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 700 PARK OFFICES DRIVE
STREET 2: SUITE 200
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
BUSINESS PHONE: 919-213-9835
MAIL ADDRESS:
STREET 1: 700 PARK OFFICES DRIVE
STREET 2: SUITE 200
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
FORMER COMPANY:
FORMER CONFORMED NAME: G-Zero Therapeutics, Inc.
DATE OF NAME CHANGE: 20121012
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2021-06-17
false
0001560241
G1 Therapeutics, Inc.
GTHX
0001184420
RUDNICK SETH
700 PARK OFFICES DRIVE, SUITE 200
RESEARCH TRIANGLE PARK
NC
27709
true
false
false
false
Common Stock
2021-06-17
4
A
false
4389.00
0.00
A
4389.00
D
Common Stock
5266.00
I
See Footnote
Stock Options (Right to Buy)
21.97
2021-06-17
4
A
false
19620.00
0.00
A
2031-06-17
Common Stock
19620.00
19620.00
D
Represents a restricted stock unit ("RSU") award that vests in its entirety twelve months after June 17, 2021, subject to the Reporting Person's continued service as a director.
Each RSU represents a contingent right to receive one share of Issuer common stock
These shares are held in the Seth A. Rudnick 2014 GST Trust U/A Dated 03/01/2014 (the "Trust") for the benefit of the Reporting Person's heirs. The Reporting Person's spouse is trustee of the Trust. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
The shares underlying this option will vest in their entirety twelve months after June 17, 2021, subject to the Reporting Person's continued service as a director.
/s/ James Stillman Hanson, attorney-in-fact
2021-06-21
EX-24
2
srudnickpoa.txt
RUDNICKPOA
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby
constitutes and appoints Anne T. Leland, Brenda L. Meyette, Jacquelyn
A. Cannata, Megan N. Gates, Peter N. Cunningham, Verna Krishnamurthy
and Hana M. Sahdev of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo,
P.C., and Barclay A. Phillips, James Stillman Hanson, Jennifer K. Moses,
Becky Daniel and Sandi James of G1 Therapeutics, Inc. signing singly,
with full power of substitution, the undersigned's true and lawful
attorney-in-fact to:
(1) execute for and on behalf of the undersigned, forms and
authentication documents for EDGAR Filing Access;
(2) do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete
and execute any such forms and authentication documents;
(3) execute for and on behalf of the undersigned, in the
undersigned's capacity as an officer, director and/or 10%
shareholder of the Company, Forms 3, 4 and 5 in accordance
with Section 16(a) of the Securities Exchange Act of 1934
and the rules thereunder;
(4) do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete
and execute any such Form 3, 4 or 5 and timely file such
form with the United States Securities and Exchange
Commission and any stock exchange or similar authority; and
(5) take any other action of any type whatsoever in connection
with the foregoing which, in the opinion of such attorney-
in-fact, may be of benefit to, in the best interest of, or
legally required by, the undersigned, it being understood
that the documents executed by such attorney-in-fact, on
behalf of the undersigned pursuant to this Power of
Attorney, shall be in such form and shall contain such
terms and conditions as such attorney-in-fact may approve
in such attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full
power and authority to do and perform any and every act and thing
whatsoever requisite, necessary, or proper to be done in the exercise
of any of the rights and powers herein granted, as fully to all
intents and purposes as the undersigned might or could do if
personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or
such attorney-in-fact's substitute or substitutes, shall lawfully do
or cause to be done by virtue of this power of attorney and the
rights and powers herein granted. The undersigned acknowledges that
the foregoing attorneys-in-fact, in serving in such capacity at the
request of the undersigned, is not assuming, nor is the Company
assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Securities Exchange Act of 1934.
This Power of Attorney shall remain in full force and effect
until the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in
securities issued by the Company, unless earlier revoked by the
undersigned in a signed writing delivered to the foregoing attorneys-
in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed this 12th day of September 2018.
/s/ Seth A. Rudnick, MD
Seth A. Rudnick, MD